John Hey, Ph.D.

Chief Scientific Officer at Alzheon.

Framingham, MA
Alzheon

Raised on Alzheon filings

$126.3M

of $150M offered across 1 Form D filing

Form D filings: 1
Teammates: 12
Last filing: Feb 10, 2025

Company

Biotech · Framingham, MA

Oral Alzheimer's drug targeting amyloid oligomers

Oral Alzheimer's drug targeting amyloid oligomers

Investors: 76
Still open: $23.7M

Investors: 76
Sector: Biotech
HQ: Framingham, MA

Alzheon filings

Alzheon Form D filings
Filed	Security	Sold of offered	Filing
Feb 10, 2025	Equity	$126.3M/ $150M	Form D/A

EquityFiled Feb 10, 2025Form D/A
$126.3M/ $150M

Works with

Also named on Alzheon filings

Martin Tolar, M.D., Ph.D.President and Chief Executive Officer, Form D signerForm D signer Muneer SatterDirector Aidan Power, MRCPsychChief Development Officer Christopher Noel DunnDirector Diane K. Jorkasky, M.D.Director Glenn E. PaulyChief Commercial Officer Kenneth A. MaceTreasurer and Chief Financial Officer Neil W. FlanzraichDirector Adem AlbayrakChief Data Officer Gino SantiniDirector Jordan HellerDirector Susan Abushakra, M.D.Chief Medical Officer